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RENAPE NetworkAbstract
Background: Rare peritoneal cancers represent complex clinical situations requiring a specific and multidisciplinary
management. Because of their rarity, lack of awareness and knowledge often leads to diagnostic delays and
misdiagnosis. And patients are not systematically referred to expert centers as they should be. Clinicians and
researchers also face unique challenges with these rare cancers, because it is hard to conduct adequately powered,
controlled trials in such small patient population. This is how an observational patient registry constitutes a key
instrument for the development of epidemiological and clinical research in the field of these rare cancers. It is the
appropriate tool to pool scarce data for epidemiological research and to assess the impact of diagnostic and
therapeutic strategies. We aimed to provide the outlines and the framework of the RENAPE observational registry
and share our experience in the establishment of a national patient registry.
Results: The RENAPE observational registry has been launched in 2010 thanks to institutional supports. It concerns
only patients with a histological diagnosis confirming a peritoneal surface malignancy. A web secured clinical
database has been implemented based on data management procedures according to the principles of
international recommendations and regulatory statements. A virtual tumor bank is linked in order to the conduct
translational studies. Specialized working groups have been established to continuously upgrade and evolve the
common clinical and histological data elements following the last classifications and clinical practices. They
contribute also to standardize clinical assessment and homogenize practices.
Conclusions: The RENAPE Registry may improve awareness and understanding of the rare peritoneal tumors into
the incidence, prevalence, recurrence, survival and mortality rates, as well as treatment practices thereby enabling
therapeutic intervention to be evaluated and ultimately optimized.
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Peritoneal carcinomatosis most commonly represents local
or regional evolution of an abdominal carcinoma. Some-
times it can be synchronous with the primary tumor (pri-
mary carcinomatosis) but more often is present as recurrent
disease (metachronous or secondary) after first-line treat-
ment of the primary tumor. When peritoneal masses are
discovered, the principal diagnostic concern is metastatic
disease, which is the most frequently encountered neoplastic
process that involves the peritoneal cavity. However, primary
peritoneal tumors should be appropriately included in the
differential diagnosis in patients presenting with diffuse or
focal peritoneal disease processes. Primary peritoneal tumors
are an uncommon group of diverse pathologic disorders
that share a common anatomic site of origin and have over-
lapping imaging features, yet are distinctly different clinic-
ally. Tumors originating from the peritoneum itself are
definitely rarer and represent complex clinical situations re-
quiring a specific management in expert centers. Differenti-
ating primary peritoneal tumors from metastatic disease is
important clinically so that patient management is appropri-
ate. An epidemiological surveillance based on a specific tool
is needed to better understand their characteristics and
evolve the standards of care.
Pseudomyxoma peritonei
Pseudomyxoma peritonei (PMP) is an uncommon clinical
entity with an estimated incidence of one to two per million
per year worldwide. According to national data based on
population, the annual incidence of PMP is 1,500 cases in
the United States of America (USA) and approximately 27
cases or 1.7 to 2 per million per year in the Netherlands.
The incidence in Asia is about one per million per year and
is presumed to be about a quarter of that in USA [1]. The
occurrence of PMP is slightly higher in women than in
men [2–4]. PMP occurs in approximately two of every
10,000 laparotomies and is more common in women with
an average age of 53 years [2]. PMP is characterized by a
gelatinous ascite associated with mucinous tumor deposits
spreading on peritoneal surface and potentially invading ab-
dominal organs [5]. PMP generally originates from a perfo-
rated appendiceal tumor. The biology of the disease is
poorly understood and no overall consensus exists on
histopathological classification, although tumors are com-
monly classified in a binary classification into Low grade
appendiceal mucinous neoplasm (LAMN) or high grade
mucinous adenocarcinoma [6–8]. The current standard of
care with curative intent involves a combination of
complete cytoreductive surgery (CRS) with hyperthermic
intraperitoneal chemotherapy (HIPEC) [9, 10]. The treat-
ment strategy is complex, associated with significant mor-
bidity and mortality and a substantial institutional, and
surgical “learning curve” [11, 12]. For selected patients, it
results in long term survival and cure [9, 13–15].Peritoneal mesothelioma
Peritoneal Mesothelioma (PM) is a rare malignancy [16].
The incidence rates (per 1,000,000) range between 0.5 and
three cases in men and between 0.2 and two cases in
women [16]. A review of non-pleural mesotheliomas using
data from surveillance, epidemiology and end results
(SEER) estimated that mesothelioma numbers are about
2,500 per year in USA, with peritoneal being about 10–20%
[17]. There is a predominance in the male population with
a sex ratio of 3:1 (male:female) [16, 18]. The median age at
diagnosis ranges from 49 to 55.7 years [19]. Occupational
and environmental asbestos exposure seems to be causative
in some cases of PM [20, 21]. Other even less frequent as-
sociations have been reported as implicated factors favoring
the development of the PM as radiation therapy, SV 40
virus, chronic peritonitis, thorium dioxide or mica exposure
[19, 22–25]. PM is locally aggressive neoplasm that com-
prises low-grade variants, such as multicystic and papillary
well-differentiated mesothelioma, and highly malignant
counterparts [26]. PM is confıned to the serosal surface of
the peritoneal cavity from the mesothelial cells overlying
peritoneum. It has long been considered a preterminal con-
dition amenable only to palliative treatment with a histor-
ical median survival of less than 12 months [22]. Over the
past decades, the combined approach of extensive CRS and
HIPEC has emerged as a therapeutic modality for this dis-
ease and is admitted as the standard of treatment offering
the longest survival and cure [27–33].
Primary peritoneal serous carcinoma
Primary peritoneal serous carcinoma (PPSC) is a rare con-
dition compared to their ovarian counterpart (6 vs. 120
women cases per million respectively) [34]. PPSC is an
extra-ovarian primary peritoneal malignancy, histologically
identical and clinically similar to advanced stage serous
ovarian carcinoma. PPSC can occur many years after ovary
removal surgery performed for benign diseases or prophy-
lactic oophorectomy. The tumor appears during adulthood
with a median age at diagnosis of 62 years [35, 36]. Women
with breast cancer type 1 (BRCA1) gene mutations present
an increased risk of developing a PPSC [35]. The thera-
peutic approach combining CRS with HIPEC has recently
demonstrated a survival benefit in patients with PPSC when
compared to those treated with surgery alone or surgery in
combination with systemic chemotherapy [37].
Peritoneal desmoplastic small round cell tumors
Desmoplastic small round cell tumor (DSRCT) is a rare
abdominal tumor but highly fatal malignancy with only
approximately 450 cases described in the literature
(among which more than 60 are case reports) since its
first description in 1991 by Gerald et al. [38, 39]. No
large population data exists regarding the epidemiology
of this tumor due to its rarity. Previous studies reported
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[40]. This tumor type has a strong tendency to spread
within the peritoneum but can also give rise to extraper-
itoneal metastases, mainly in the liver and lungs [39, 41].
A unique chromosomal translocation t(11;32)(p13;q12),
of the Ewing sarcoma gene breakpoint region 1
(EWSR1) on 22q13 and the Wilms tumor gene (WT1)
on chromosome 11p13 is highly specific and allows a
formal diagnosis of DSRCT [42]. Without large series in
the literature, standard of care for treatment of DSRCT
remains unclear and challenging. However a multimod-
ality approach with chemotherapy, surgery and radio-
therapy appears to represent optimal management [39].
Diffuse peritoneal leiomyomatosis
Diffuse peritoneal leiomyomatosis (DPL) is rare disease.
Fewer than 150 cases have been reported in the literature
to date. DPL is characterized by the proliferation of mul-
tiple benign smooth muscle cell-containing nodules in the
peritoneal cavity. DPL manifests during adulthood and is
predominantly found in women. Only one case of DPL
has been reported in a male [43]. Malignant transform-
ation is rare and in a few cases [44]. Etiology is unknown
but DPL seems to be a multifactorial disease with a
genetic or hormonal component leading to metaplasia of
peritoneal mesenchymal cells [45, 46]. Depending on the
extent of the disease, first-line treatment for DPL is surgi-
cal excision or CRS [47].
The establishment of a the French network for rare
peritoneal tumors (RENAPE) reference networks with a
clinical database linked to a virtual tissue bank aims to
improve outcomes and make easier the exchange of ex-
perience, information, data and best practices on rare
peritoneal malignancies (RPM) amongst all stakeholders
[48]. Because of establishing a patient registry is a com-
plex process which requires a range of technical and
organizational skills; this paper aims to provide a frame-
work for the implementation of a patient registry in the
field of RPM and includes the important aspects that
need attention during this process.
Methods
Objectives and scope
By definition, a registry is “an organized system that uses
observational study methods to collect uniform data
(clinical and others) from individual patient to evaluate
specified outcomes for a population defined by a par-
ticular disease, condition or exposure, and that serves
one or more predetermined scientific, clinical, or policy
purposes” [49]. The RENAPE Registry has been
launched in 2010. It aims to monitor more prevalence
and incidence of RPM in France, to establish natural his-
tory of these rare cancers. It is also intended to assess
the clinical effectiveness of new interventions, tomeasure the quality of care and to provide an inventory
of patients to re-contact for participation in epidemio-
logical studies, clinical trials or for health technology as-
sessment to monitor real access to treatments.Institutional support
The RENAPE Observational Registry benefits the full
support of the national patients association against RPM
(AMARAPE) and is endorsed by French National Can-
cer Institute (INCa) as a global priority in the field of
Rare Cancer. It is also partner of the European Platform
for Rare Disease Registries (EPIRARE) co-funded by the
European Commission within the European Union Pro-
gram of Community Action in the field of Public Health.Ethical and legal statements
The RENAPE Observational Registry complies with ap-
plicable local regulations and with the ethical principles
laid down in the Declaration of Helsinki (Fortaleza 2013).
The RENAPE Observational Registry has been approved
by the Advisory Committee for Data Processing in Health
Research at the Research French Ministry (CCTIRS -
n°10.257). The RENAPE Observational Registry has
been registered with French Data Protection Author-
ity (CNIL - no. DR-2010-297) in accordance with the
French Law 78-17 dated January 6th, 1978 relating to
data processing, files and personal freedom and
privacy.Patient population
The RENAPE Observational Registry includes only
patients with RPM such as peritoneal mesothelioma
(ORPHA168811/168816), pseudomyxoma peritonei
(ORPHA26790), primary peritoneal serous carcinoma
(ORPHA168829), peritoneal desmoplastic small round
cell tumors (ORPHA83469), diffuse peritoneal leiomyo-
matosis (ORPHA71274). All patients were required a
confirmation of histological diagnosis as determined by
an expert pathologist [48]. The RENAPE Observational
Registry database concerns only persons whose usual
place of residence is France.Registry design
The RENAPE Observational Registry is a retrospect-
ive, longitudinal patient registry that has been imple-
mented through a secure, fully Web-based application
(EOL©). It has been launched as an open-ended pro-
ject without a pre-defined stopping point. The access
to the registry application has currently been opened
at all specialized French centers with expertise in the
treatment of RPM [48].
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For each new patient a minimal data set is required
(Table 1) including identification, demographic information
and etiology. The RENAPE Observational Registry employs
internal record linkage to identify and eliminate duplicate
patient and tumor records. Each entry in the registry has a
unique identifier (alphanumeric code). Identification codes
are stored in an independent and safe database according
to the French Data Protection Act. Patients are written and
oral informed that a pseudonymisation method replacing
any identifying characteristics of registered personal data
with a pseudonym (alphanumeric code) provides a limited
protection for the identity of data subjects. However all ag-
gregated data or results provided from the registered data
are strictly anonymous. The clinical data capture will be up-
dated appropriately based on each patient’s clinical manage-
ment. Clinical data are directly collected in a standard
format by the clinicians. A resource person – a clinical re-
search assistant – with specialized knowledge in the clinical
pathways of the RPM - is provided by the coordination of
the RENAPE Registry in order to help sites on data entry
process. The RENAPE Registry common data elements are
organized into 9 categories: patient information, preopera-
tive work-up, peroperative data and 90-day postoperative
follow-up (Table 2) and long term follow-up. We use pref-
erentially appropriate scores (Peritoneal Cancer Index -
PCI, completeness of cytoreduction score - CC-score) and
validated classifications (CTCAE). Clear, operational defini-
tions of data elements and standard instructions were pro-
vided to collect data consistently. At each participating site,
a local pathologist validates and records histological sub-
type and grade of tumor on extended data set available to
capture pathological details (Table 3). Correlation edits
check the compatibility of different data elements within a
record. These verifications are done as data are loaded into











Primary peritoneal serous carcinoma
Peritoneal desmoplastic small round cell tumors
Diffuse peritoneal leiomyomatosisreturned to the participating sites for verification and/
or correction. The data management procedures fol-
low in accordance with the principles of Good Clin-
ical Practices (GCP). The scope of these standard
operating procedures is to: staff training and qualifica-
tions, case inclusion, case ascertainment, procedures
for adding new cases to the permanent data set, rules
for updating or changing data on file, follow-up, data
exchange. Data quality is assured by pre-testing and
consistency checks during data entry, when applicable.
Data originate from various sources and specific at-
tention is taken to avoid duplicate information.
Data protection
The EOL© application is validated under 21 Code of Fed-
eral Regulations criteria (CFR Part 11) [50]. Data protec-
tion is based on the definition of authorization profiles,
defining the functions or types of information available to
a user. The access to the electronic data capture applica-
tion is controlled by personal username and password
generated by the administrator. All recorded data must be
validated by electronic signature. An audit trail module al-
lows tracking of all accesses, modifications, and deletions
of data. All exported files are archived with history within
the system. The automatic identification of patients with-
out nominative data enables an interoperability of the data
recorded and remains pseudonymous. The RENAPE
Registry benefits of a safe and secure hosting in France
based on Information Technology Infrastructure Library
(ITIL) security management (version 3).Follow up data
The RENAPE registry devotes substantial efforts to engage
participating physicians in the registry to minimize and
monitor loss to follow-up. If the patient has returned to
the facility, records are obtained and appropriate informa-
tion extracted. Physicians route the record to the RENAPE
Registry coordination team. If the patient has not returned
to the institution, follow-up letters are usually mailed to
the managing or referring physician. Letters may be sent
to other physicians involved in the care of the patient. A
date of last contact should be requested in the letter for
the patient or contact to complete (Table 4).
Results and discussion
Rare cancer patient registries as the RENAPE Registry rep-
resent a fundamental research tool for increasing know-
ledge on rare cancers by pooling data for fundamental and
clinical research, epidemiological research. Patient registries
and databases constitute key instruments for the develop-
ment of clinical research in the field of rare cancers such
RPM. They are the appropriate way to conduct research on
populations and conditions that are not generally studied in
Table 2 Common clinical data elements
Patient information
Contact details
Current or past professional activity
Medical contact details
Personal and family relevant medical history
Preoperative work
Occupational/environmental exposure (asbestos, erionite, mica,
etc.)
Etiology
Diagnosis date and circumstances
Height
Weight
Imaging: MRI, CT-TDM, PET scan
Biology: tumor markers, creatinine
Neoadjuvant treatments:
PIPAC
Chemotherapy: dates, no. cycles, regimen
Radiotherapy: dates, dose (Gy)













Type of postoperative analgesia
90-day postoperative follow-up


















Abbreviations: CCR completeness of cytoreduction, CRS cytoreductive surgery,
CTCAE Common Terminology Criteria for Adverse Events, HIPEC Hyperthermic
Intraperitoneal Chemotherapy, ICU Intensive Care Unit, PCI Peritoneal Cancer
Index, PIPAC pressurized intraperitoneal aerosol chemotherapy
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and for clinical decision-makers [51] because they offer the
opportunity to assess the feasibility of clinical trials, to
facilitate the planning of appropriate clinical trials and to
support the enrolment of patients. Because of its non-
experimental design (i.e., no randomization), the present
registry can be used to examine the impact of physician
practice behaviors on quality of care.
The RENAPE Registry is based upon the voluntary par-
ticipation of the centers, the percentage of institutions
participating is high with all HIPEC French centers in-
cluding international expert teams members of the Peri-
toneal Surface Oncology Group International (PSOGI).
Unparticipating centers are usually low-volume centers,
so that our data are likely skewed towards management
practices that are mostly used in larger-volume centers.
Therefore the RENAPE Registry is to be considered as a
specialized patient-based registry. It doesn’t meet strictly
the exhaustiveness criteria required for a nationwide
population-based cancer registry. To optimize data quality
and exhaustiveness, experienced clinical research re-
sources help the centers to complete the data integrity.
One of the main strength of the present registry is that de-
tailed data are recorded to characterize patient clinical
and pathological features, their multidisciplinary manage-
ment and outcomes. Overall more than 500 fields have to
be filled-in. The consistent longitudinal collection of pa-
tient data facilitates the creation of standards of care and
dramatically improves patient outcomes even in the ab-
sence of new therapies [52]. Data collected also allow the
impact therapeutic strategies and clinical practices to be
assessed. Furthermore, the RENAPE registry benefits from
the many advantages offered by the EOL© application:
privacy and security of the data; flexibility and scalability,
simplicity and fast implementation. Therefore, the registry
is always in evolution to stick to novel standard of care or
classification. The experience and multidisciplinary of ac-
tive contributors allow to continuously evolve this com-
mon tool and clinical, histological items from database are
upgraded. The RENAPE network organization has
Table 4 Long term follow-up data
Date of last contact
Vital status
Date of death
Primary cause of death
Recurrence
Date of recurrence









Systemic chemotherapy: dates, no. cycles, regimen
Radiotherapy: dates, dose (Gy)
PIPAC: dates, regimen, doses
Participation at a clinical trial
Abbreviation: PIPAC pressurized intraperitoneal aerosol chemotherapy



















Ronnett classification: DPAM, PMCA-I/D, PMCA
WHO 2010 Classification: LAMN, high-grade mucinous
adenocarcinoma
Involved organs (list)









Lymph node involvement: pNtot, pN+
Primary peritoneal serous carcinoma/peritoneal desmoplastic small
round cell tumors/diffuse peritoneal leiomyomatosis
Diagnostic
No. blocks
Lymph node involvement: pNtot, pN+
Abbreviations: DPAM disseminated peritoneal adenomucinosis, LAMN low-grade
appendiceal mucinous neoplasm, PMCA peritoneal mucinous carcinomatosis,
PMCA-I/D peritoneal mucinous carcinomatosis with intermediate or discordant
features, pNtot total number of dissected nodes, pN+ number of involved nodes
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cialized working group that participate at the process
of defining consensus criteria and nomenclature for
appendiceal tumors under the auspices of the PSOGI
[7, 53]. The RENA-PATH Group also leads collabora-
tive translational research projects based on thevirtual biobank linked to the Registry clinical database
[54, 55]. Biocollection is disseminated and locally
stored in all associated biological resource centers
(BSR). In translational collaborative studies, the
RENAPE registry is used to screen patient population
concerned and to provide survival data. Then analyses
are only conducted on available biospecimens for
which patients have given their local written consent.
The RENA-RAD Working Group has been formed re-
cently with expert radiologists in peritoneal carcin-
omatosis imaging [56]. They share experiences and
develop common tools in order to standardize radio-
logical assessment of patients who are suitable for
CRS with HIPEC.
A multidisciplinary care management is required
among clinicians, surgeons and experts from the
RENAPE network in order to improve patient selec-
tion and optimize survival outcomes. Specialists use
transversal tools for quantitative and qualitative
assessment of patients who are suitable for surgical
treatment. The PROMISE® internet application has
been developed to allow for a standardized assess-
ment of the peritoneal disease extent intended of
multidisciplinary teams and centers that treat patients
with RPM [56].
The RENAPE Registry’s implementation will clearly
rise up to offer the opportunity to fill in important gaps
in knowledge about RPM, through national and inter-
national collaborations [9, 33, 39, 53, 57, 58].
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The rarity of the RPM and their diagnostic uncertainties
limit our understanding of its epidemiological features.
There is therefore a clear need - recognized by specialists
throughout France – for a specific RPM Observational
Registry. The information collected from the RENAPE
Registry will improve awareness and understanding of the
RPM into the incidence, prevalence, recurrence, survival
and mortality rates, as well as treatment practices thereby
enabling therapeutic intervention to be evaluated and ul-
timately optimized. The Registry will also enable clinicians
to review the prognosis of different patient groups and
identify long-term therapeutic benefits of therapeutic in-
terventions. The multi-institutional nature of the project
and web-based database structure permit easy data entry
and provide a mechanism to scale the RENAPE Registry
to a larger consortium of contributing institutions.Abbreviations
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